Diagnóstico y tratamiento del mesotelioma pleural maligno

Panadero, Francisco Rodríguez

doi:10.1016/j.arbres.2014.06.005

Cited by 25 publications

(14 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The general recommendations from the different pathologists worldwide for the diagnosis of MPM still advocate the use of an immunohistological examination of a conventionally stained tissue samples as the gold standard for MPM diagnosis [5, 118, 139, 140]. It still takes several months between the first signs of the disease and a definite diagnosis of MPM is achieved.…”

Section: Resultsmentioning

confidence: 99%

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Cortes-Dericks

Schmid

2017

Respir Res

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient serum are reasonable options to provide a faster and noninvasive diagnostic approach. As yet, the current biomarkers for MPM lack specificity and sensitivity to discriminate this neoplasm from other lung tumors. CD44, a multifunctional surface receptor has been implicated in tumor progression in different cancers including MPM. The interaction of CD44 with its ligand, hyaluronan (HA) has demonstrated an important role in modulating cell proliferation and invasiveness in MPM. In particular, the high expression levels of these molecules have shown diagnostic relevance in MPM. This review will summarize the biology and diagnostic implication of CD44 and HA as well as the interaction of both molecules in MPM that will demonstrate their potential as biomarkers. Augmentation of the current markers in MPM may lead to an earlier diagnosis and management of this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Cortes-Dericks

Schmid

2017

Respir Res

View full text Add to dashboard Cite

show abstract

“…Wierman et al reported in 1954 that HOA was present in 60% of fibrous tumors of the pleura 8. In their paper, the detailed correlation between malignant mesothelioma and HOA was not described, and immunostaining, which is considered essential to diagnose malignant mesothelioma, was not performed 9. The diagnosis of malignant mesothelioma was immunohistochemically confirmed in our patient.…”

Section: Discussionmentioning

confidence: 55%

A case of severe arthralgia with malignant mesothelioma‐associated hypertrophic osteoarthropathy

Yamakawa

Sekine

Kato

et al. 2016

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…On the rare occasion that TB and malignancy coincide, a pleural biopsy would still be required despite use of the isoenzyme assay. 41 Early in TB pleural disease the ADA levels may be low, however, repeat thoracentesis usually demonstrates the expected elevation along with increasing lymphocyte counts. 42 ADA levels may be falsely low in elderly patients and current smokers with TB pleurisy, and falsely elevated in rheumatoid pleural effusions, bacterial pleural infection, mesothelioma, lung cancer and haematological malignancies especially lymphoma.…”

Section: Adenosine Deaminasementioning

confidence: 99%

Pleural tuberculosis: A concise clinical review

Shaw

Irusen

Diacon

et al. 2018

Clinical Respiratory J

View full text Add to dashboard Cite

Tuberculosis (TB) is the leading infectious cause of death worldwide, and the commonest cause of death in people living with HIV. Globally, pleural TB remains one of the most frequent causes of pleural exudates, particularly in TB-endemic areas and in the HIV positive population. Most TB pleural effusions are exudates with high adenosine deaminase (ADA), lymphocyte-rich, straw-coloured and free flowing, with a low yield on mycobacterial culture. TB pleurisy can also present as loculated neutrophil-predominant effusions which mimic parapneumonic effusions. Rarely, they can present as frank TB empyema, containing an abundance of mycobacteria. Up to 80% of patients have parenchymal involvement on chest imaging. The diagnosis is simple if M. tuberculosis is detected in sputum, pleural fluid or biopsy specimens, and the recent advent of liquid medium culture techniques has increased the microbiological yield dramatically. Where the prevalence of TB is high the presence of a lymphocyte-predominant exudate with a high ADA has a positive predictive value of 98%. In low prevalence areas, the absence of an elevated ADA and lymphocyte predominance makes TB very unlikely, and pleural biopsy should be performed to confirm the diagnosis. Pleural biopsy for liquid culture and susceptibility testing must also be considered where the prevalence of drug resistant TB is high. Treatment regimens are identical to those administered for pulmonary TB. Initial pleural drainage may have a role in symptom relief and in hastening the resolution of the effusion. Surgical intervention may be required in loculated effusions and empyemas.

show abstract

Diagnóstico y tratamiento del mesotelioma pleural maligno

Cited by 25 publications

References 94 publications

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

A case of severe arthralgia with malignant mesothelioma‐associated hypertrophic osteoarthropathy

Pleural tuberculosis: A concise clinical review

Contact Info

Product

Resources

About